Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지

Outcome of Gonadotropin Therapy for Infertile Men with Hypogonadotropic Hypogonadism

저성선자극호르몬 성선저하증 (Hypogonadotropic Hypogonadism)으로 진단된 남성불임 환자에서 성선자극호르몬 (Gonadotropin) 치료가 정자형성 및 임신에 미치는 영향

  • Joo, Young-Min (Department of Urology, Cheil General Hospital, Kwandong University College of Medicine) ;
  • Kim, Tae-Hong (Department of Urology, Cheil General Hospital, Kwandong University College of Medicine) ;
  • Seo, Ju-Tae (Department of Urology, Cheil General Hospital, Kwandong University College of Medicine)
  • 주영민 (관동대학교 의과대학 제일병원 비뇨기과) ;
  • 김태홍 (관동대학교 의과대학 제일병원 비뇨기과) ;
  • 서주태 (관동대학교 의과대학 제일병원 비뇨기과)
  • Published : 2009.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Hypogonadotropic hypogonadism (HH) is an uncommon cause of male infertility. We investigated the outcome of gonadotropin therapy for restoring fertility and pregnancy outcomes in patients with HH. Methods: Medical charts of 10 infertile male patients with HH treated with gonadotropin were reviewed. Initial testicular volume were estimated. Semen analysis parameters (semen volume, sperm counts, motility), serum leutenizing hormone (LH), follicle stimulating hormone (FSH), total testosterone were determined before and after human chorionic gonadotropin/human menopausal gonadotropin (hCG/hMG) treatment. Differences were analyzed statistically. Results: Of 10 patients, 7 (70%) succeed at pregnancy (nature pregnancy in 4). Semen analysis parameters, serum FSH, and testosterone were increased significantly after treatment. The population was stratified according to initial testicular volume into a small testis subset (testicular volume less than 10 cc in 4) and a large testis subset (testicular volume 10 cc or greater in 6). Semen analysis parameters and serum testosterone were increased significantly after treatment in large testis subset. Conclusion: Infertile men with HH initiate and maintain spermatogenesis with gonadotropin (hCG/hMG alone or combined) therapy, thus gonadotropin therapy is good choice in infertile men with HH.

목 적: 저성선자극호르몬 성선저하증은 남성불임의 흔치 않은 원인이다. 저자들은 성선자극호르몬 특히 인간융 모성선자극호르몬 (Human chorioinc gonadotropin: hCG)/인간폐경성선자극호르몬 (Human menopausal gonadotropin: hMG) 치료가 정자형성 및 임신에 미치는 영향에 대해 알아보았다. 연구방법: 2001년 11월부터 2007년 3월까지 불임을 주소로 내원하여 저성선자극호르몬 성선저하증으로 진단되어 성선자극호르몬 (hCG/hMG) 치료를 받은 10명의 진료 기록을 후향적으로 분석하였다. 치료 후 임신 여부를 알아보았으며, 치료 전 고환의 용적에 따라 10 cc 미만인 군 (n=4)과 10 cc 이상인 군 (n=6)으로 나누어 치료 전후의 정액지표와 혈중 FSH, LH 및 testosterone 등의 호르몬 검사를 시행하여 비교하였다. 결 과: 10명의 환자 중 7명 (70%)에서 임신에 성공하였으며 치료 후 혈중 FSH, testosterone 수치가 의미있게 증가하였다. 고환 용적이 큰 군에서 치료 후 정액량, 정자수, 운동성 및 testosterone이 유의하게 증가하였다. 결 론: 불임을 주소로 온 환자에게 흔치는 않지만 면밀한 검사를 통해 저성선자극호르몬 성선저하증을 진단할 수 있어야 하며, hCG/hMG 병합요법은 자연임신 뿐만 아니라 최근의 보조생식술과 연계하여 충분히 성공적인 치료에 도달할 수 있다.

Keywords

References

  1. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocrine practice 2002; 8: 439-56 https://doi.org/10.4158/EP.8.6.439
  2. Sigman M, Jarow JP. Endocrine evaluation of infertile men. Urology 1997; 50: 659-64 https://doi.org/10.1016/S0090-4295(97)00340-3
  3. Sigman M, Jarow JP. Male Infertility. In Walsh PC, Retik AB, Vanghan ED Jr, Wein A. Jc, editors. Campbell's Urology 9th ed, Philadelphia: Saunders, 2007; 609-53
  4. Miyagawa Y, Tsujimura A, Matsumiya K, Takao T, Tohda A, Koga M, et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study. J Urol 2005; 173: 2072-5 https://doi.org/10.1097/01.ju.0000158133.09197.f4
  5. Buchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol 1998; 139: 298-303 https://doi.org/10.1530/eje.0.1390298
  6. D'Agta R, Vicari E, Allifi A, Mauqeri G, Monqioi A, Gulizia S. Tesiticular responsiveness to chronic human chorionic gonadotropin administration in hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1982; 55: 76-80 https://doi.org/10.1210/jcem-55-1-76
  7. Vicari E, Mongioi A, D'Agta R. Gonadotropin replacement therapy in patients with hypogonadotropic hypogonadism. Ann N Y Acad Sci 1984; 438: 454-8 https://doi.org/10.1111/j.1749-6632.1984.tb38306.x
  8. Rey RA, Campo SM, Bedecarras P, Nagle CA, Chemes HE. Is infancy a quiescent period of testicular development? Histological, morphometric, and functional study of the seminiferous tubules of the cebus monkey from birth to the end of puberty. J Clin Endocrinol Metab 1993; 76: 1325-31 https://doi.org/10.1210/jc.76.5.1325
  9. Russell LD, Bartke A, Goh JC. Postnatal development of the Sertoli cell barrier, tubular lumen, and cytoskeleton of Sertoli and myoid cells in the rat, and their relationship to tubular fluid secretion and flow. Am J Anat 1989; 184: 179-89 https://doi.org/10.1002/aja.1001840302
  10. Bardin CW. Male Hypogonadism. In: Yen SSC, Jaffe RB, editors. Reproductive Endocrinology, Physiology, Pathophysiology and Clinical Management. 2nd ed. Philadelphia: Saunders; 1986; 614-30
  11. Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am 1994; 23: 857-75
  12. Burris AS, Rodbard HW, Winters SJ, Sherins RJ. Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. J Clin Endocrinol Metab 1988; 66: 1144-51 https://doi.org/10.1210/jcem-66-6-1144